Literature DB >> 22717453

Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.

Marte Lie Høivik1, Bjørn Moum, Inger Camilla Solberg, Magne Henriksen, Milada Cvancarova, Tomm Bernklev.   

Abstract

OBJECTIVE: To compare the work disability (WD) rate in inflammatory bowel disease (IBD) patients 10 years after disease onset, with the WD rate in the background population,and to assess whether clinical or demographic factors in the early disease course could predict WD after 10 years disease.
DESIGN: A large, population-based inception cohort (the Inflammatory Bowel in South Eastern Norway cohort) was prospectively followed up at 1, 5 and 10 years after diagnosis. At the 10-year follow-up data on WD were collected. Data on disability pension (DP) in the background population were retrieved from public databases. We calculated overall and age-standardised relative risks (RR) for DP. Logistic regression analysis was used to examine predictive factors.
RESULTS: A total of 518 patients completed the 10-year follow-up (response rate 83.5%). The overall disability rate in the IBD population was 18.8%, and the RR was 1.8 (95% CI 1.4 to 2.3) for ulcerative colitis (UC) and 2.0 (95% CI 1.4 to 2.7) for Crohn's disease (CD). The RR for DP was highest in patients aged below 40 years while patients aged over 60 years had no increased RR. Steroid treatment at the 1-year follow-up predicted WD after 10 years disease in both CD and UC. In UC, increased C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) at diagnosis, early colectomy, and more than two relapses during the first year of the disease also predicted WD.
CONCLUSION: Ten years after disease onset IBD patients had an increased RR for DP as compared with the background population. The youngest patients had the highest RR. Markers of severe disease course predicted WD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717453     DOI: 10.1136/gutjnl-2012-302311

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  68 in total

1.  IBD-related work disability in the community: Prevalence, severity and predictive factors. A cross-sectional study.

Authors:  Alexis Ramos; Xavier Calvet; Beatriz Sicilia; Mercedes Vergara; Ariadna Figuerola; Jaume Motos; Adoración Sastre; Albert Villoria; Fernando Gomollón
Journal:  United European Gastroenterol J       Date:  2015-08       Impact factor: 4.623

2.  Measuring Disability in IBD: The IBD Disability Index.

Authors:  Jean-Frédéric Colombel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-05

3.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

Review 4.  Inflammatory bowel disease: a Canadian burden of illness review.

Authors:  Angela Rocchi; Eric I Benchimol; Charles N Bernstein; Alain Bitton; Brian Feagan; Remo Panaccione; Kevin W Glasgow; Aida Fernandes; Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2012-11       Impact factor: 3.522

Review 5.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

6.  Prescription Opioids induce Gut Dysbiosis and Exacerbate Colitis in a Murine Model of Inflammatory Bowel Disease.

Authors:  Umakant Sharma; Rohini Khatri Olson; Federico Nicolas Erhart; Li Zhang; Jingjing Meng; Bradley Segura; Santanu Banerjee; Madhulika Sharma; Ashok Kumar Saluja; Sundaram Ramakrishnan; Maria T Abreu; Sabita Roy
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

Review 7.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

8.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

9.  A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.

Authors:  Gang Zhao; Xin Wei; Jianbo Wu; Derrick D Eichele; Subodh M Lele; Libin Yang; Fan Zhang; Dong Wang
Journal:  Pharm Res       Date:  2019-03-11       Impact factor: 4.200

Review 10.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.